ML-2 Xenograft Model Service for AML

The ML-2 cell line, derived from a patient with acute myeloid leukemia (AML), provides a sophisticated and translationally relevant in vivo platform for investigating the molecular drivers of myeloid malignancies and assessing the therapeutic efficacy of novel antileukemic compounds. As an industry-leading pre-clinical contract research organization, Alfa Cytology offers an integrated, high-precision ML-2 Xenograft Model Service, meticulously engineered to provide reproducible, robust datasets that accelerate your AML drug discovery and development pipeline.

Overview of ML-2 Xenograft Model for AML

The ML-2 xenograft model serves as a specialized, genetically characterized in vivo translational tool widely utilized in hematological oncology research, particularly for studying AML subtypes with specific chromosomal translocations. By transplanting human ML-2 myeloblastic cells into highly permissive immunodeficient mouse hosts, this system effectively recapitulates the systemic dissemination, leukemic cell bone marrow homing, and peripheral blood pathophysiological profiles characteristic of progressive human AML.

Biologically, the ML-2 model is highly valued for its stable engraftment parameters and proliferative consistency, offering pre-clinical researchers a reliable experimental window for conducting rigorous pharmacological assessments. The platform preserves key human myeloid molecular features, including lineage-specific surface markers and altered intracellular signaling cascades, which are essential for evaluating the anti-leukemic potency of targeted small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens. This model facilitates a comprehensive understanding of leukemic progression dynamics in an in vivo environment, ensuring that therapeutic responses are evaluated with high physiological relevance.

Fig 1. Bacteria circumvent APO866-induced anti-leukemic activities by activating the Preiss-Handler pathway to synthesize NAD+. (ElMokh O, et al., 2022)

Cell Line Information: ML-2

The ML-2 cell line was established from the peripheral blood of a patient diagnosed with AML. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a consistent myeloblastic phenotype that serves as a robust proxy for modern hematological cancer studies.

Our Services

Workflow of ML-2 Xenograft Model Construction

• Cell Culture & Quality Control: Human ML-2 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunocompromised mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability ML-2 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. ML-2 Xenograft Model Construction Workflow

Case Study - ML-2 Xenograft Model Development

A pre-clinical validation study was conducted using the ML-2 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting myeloid cell survival signaling in AML. Following precision intravenous inoculation of human ML-2 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals in the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our ML-2 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.